Literature DB >> 10333981

Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission.

N Haddjeri1, P Blier, C de Montigny.   

Abstract

Mirtazapine (ORG 3770, Remeron) is a new alpha 2-adrenoceptor antagonist which has been shown to be an effective antidepressant drug. The aims of the studies were to assess, using an in vivo electrophysiological paradigm in the rat, the effects of acute and long-term treatment with mirtazapine on pre- and postsynaptic alpha 2-adrenoceptors and to determine whether this drug could modulate serotonin (5-HT) neurotransmission. Acute administration of mirtazapine produced a transient increase of the firing activity of dorsal raphe 5-HT neurons. This effect was mediated via norepinephrine (NE) neurons because it was abolished in NE-lesioned rats. In fact, this increased firing rate of 5-HT neurons was due to their activation by the enhanced release of NE resulting from the blockade of alpha 2-adrenergic autoreceptors of locus coeruleus neurons. Furthermore, acute mirtazapine injection transiently enhanced the firing activity of locus coeruleus NE neurons and attenuated the suppressant effect of the alpha 2-adrenoceptor agonist clonidine on these NE neurons. Sustained administration of mirtazapine for 21 days (5 mg/kg/day, s.c., using minipumps) lead to a marked increase in the firing rate of 5-HT neurons (75%) but a more modest increase in the firing rate of NE neurons (30%), as well as to a desensitization of alpha 2-adrenergic heteroreceptors on 5-HT terminals in the hippocampus. The desensitization of these heteroreceptors, resulting from an increased synaptic availability of NE induced by mirtazapine would free 5-HT terminals from the inhibitory influence of NE on 5-HT release. These modifications of 5-HT neurons lead to an increased tonic activation of postsynaptic 5-HT1A receptors. The latter conclusion was based on the capacity of the selective 5-HT1A receptor antagonist WAY 100635 to enhance the firing activity of dorsal hippocampus CA3 pyramidal neurons in mirtazapine-treated rats but not in controls. This enhanced 5-HT neurotransmission may underlie to the antidepressant effect of mirtazapine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10333981     DOI: 10.1016/s0165-0327(98)00223-7

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  19 in total

1.  Mirtazapine to reduce methamphetamine use: a randomized controlled trial.

Authors:  Grant N Colfax; Glenn-Milo Santos; Moupali Das; Deirdre McDermott Santos; Tim Matheson; James Gasper; Steve Shoptaw; Eric Vittinghoff
Journal:  Arch Gen Psychiatry       Date:  2011-11

2.  Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

3.  Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission.

Authors:  Olga Chernoloz; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

4.  A heuristic model for working memory deficit in schizophrenia.

Authors:  Zhen Qi; Gina P Yu; Felix Tretter; Oliver Pogarell; Anthony A Grace; Eberhard O Voit
Journal:  Biochim Biophys Acta       Date:  2016-05-10

5.  Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands.

Authors:  J E Bermack; G Debonnel
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats.

Authors:  Robin M Voigt; Amanda L Mickiewicz; T Celeste Napier
Journal:  Behav Brain Res       Date:  2011-07-12       Impact factor: 3.332

Review 7.  Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside.

Authors:  Steven M Graves; Roueen Rafeyan; Jeffrey Watts; T Celeste Napier
Journal:  Pharmacol Ther       Date:  2012-08-29       Impact factor: 12.310

8.  Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization.

Authors:  Anne Dekeyne; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

Review 9.  Mirtazapine: a review of its use in major depression and other psychiatric disorders.

Authors:  Katherine F Croom; Caroline M Perry; Greg L Plosker
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder.

Authors:  Olga Chernoloz; Mostafa El Mansari; Pierre Blier
Journal:  Psychopharmacology (Berl)       Date:  2009-07-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.